• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of chemotherapy according to induction of DNA Topoisomerase activity.

Research Project

Project/Area Number 07671325
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field General surgery
Research InstitutionSaitama Medical School

Principal Investigator

ANZAI Haruyuki  SAITAMA MEDICAL SCHOOL,FIRST DEPARTMENT OF SURGERY,ASSISTANT PROFESSOR, 医学部, 講師 (30193098)

Co-Investigator(Kenkyū-buntansha) 門倉 正樹  埼玉医科大学, 医学部, 講師 (80224559)
Project Period (FY) 1995 – 1996
Project Status Completed (Fiscal Year 1996)
Budget Amount *help
¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1996: ¥800,000 (Direct Cost: ¥800,000)
KeywordsDNA TOPOISOMERASE / TOPOTECAN / ETOPOSIDE / トポイソメラーゼI / トポイソメラーゼII / 化学療法 / トポテカン / エトポシド / 大腸癌 / トポイソメラーゼ / Topotecan.(トポテカン) / Etoposide(エトポシド)
Research Abstract

Topoisomerase (Topo) I and II activities against each cell line were related to ED50 of Topo I and II inhibitor. The cell line which indicated. high activity of Topo is very sensitive to Topo inhibitor as the target of this enzyme.
Sequential administration of Topo I and II inhibitor revealed more synergistic effect compared to simultaneous administration of these inhibitor. In addition, the precedent administration of ED10 Topo inhibitor increase the cytocidal effect of complementary Topo inhibitor synergistically. Especially, this phenomenon was observed in the cell line which showed high activity of Topo I when Topo I inhibitor were exposed precedentally.
The induction of Topo enzyme activity were studied due to Topo I and II inhibitor. But this phenomenon could not observed although Topo enzyme activity at 2,4,8,12,24 hr after the exposure of ED10,50 Topo inhibitor were measured.
Optimal dose and schedule for the induction of Topo enzyme activity could not find out in vivo condition, neither.
Therefore, although induction of Topo enzyme activity could not detected we concluded that measurement of Topo I and II enzyme activity, and following administration of Topo inhibitor against higher Topo activity of the cancer cell and precedent administration of Topo inhibitor against weak enzyme activity must be important in the clinical apply for the colon cancer chemotherapy.

Report

(3 results)
  • 1996 Annual Research Report   Final Research Report Summary
  • 1995 Annual Research Report

URL: 

Published: 1996-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi